Results 31 to 40 of about 11,700 (225)
Frontiers in Medicine, 2022 ObjectiveAs monotherapy is insufficient for some patients, the existing fixed-dose combination (FDC) requires two or more daily administrations with declining adherence.
Nachuan Luo +9 more
doaj +1 more source
Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacy [PDF]
, 2011 BACKGROUND: The purpose of this paper was to demonstrate the use of an online service for conducting a systematic review and meta-analysis of the efficacy of topical prostaglandin analogs in reducing intraocular pressure (IOP) in glaucoma and ocular ...
Burk, Caroline +4 more
core +3 more sources
Folia Morphologica, 2022 BACKGROUND: Glaucoma is a group of eye diseases that can cause vision loss. Prostaglandin analogues (PGAs) are known to be first-line treatment for patients with glaucoma.
A. F. Ali, R. M. Salama, M. A. Soliman
doaj +1 more source
Matrix Metalloproteinases and Glaucoma Treatment. [PDF]
, 2020 Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade extracellular matrix (ECM) components such as collagen and have important roles in multiple biological processes, including development and tissue remodeling, both in ...
Dibas, Mohammed +3 more
core
Rare diseases leading to childhood Glaucoma. epidemiology, pathophysiogenesis, and management [PDF]
, 2015 Noteworthy heterogeneity exists in the rare diseases associated with childhood glaucoma. Primary congenital glaucoma is mostly sporadic; however, 10% to 40% of cases are familial. CYP1B1 gene mutations seem to account for 87% of familial cases and 27% of
Abdolrahimzadeh, Solmaz +5 more
core +3 more sources
Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study. [PDF]
, 2020 Background:Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the ...
Cioffi, George A +4 more
core
Profilatic use of apraclonidine and latanoprost to prevent intraocular pressure elevation following Nd:YAG laser posterior capsulotomy [PDF]
, 1999 Purpose: To compare the efficacy of 0.005% latanoprost and 1% apraclonidine in the prevention of an increase of intraocular pressure (IOP) after Nd: YAG laser capsulotomy in nonglaucomatous patients. Methods: Thirty-six patients were included and divided
Nassaralla Júnior, João Jorge +2 more
core +2 more sources
24-h Efficacy of Glaucoma Treatment Options [PDF]
, 2016 Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss.
Banu, Bozkurt. +8 more
core +2 more sources
Journal of Ophthalmology, 2018 Objective. A prospective study was performed to observe the effects of nonsteroidal anti-inflammatory drug (NSAID) eyedrops on intraocular pressure (IOP) and the ocular surface in primary open-angle glaucoma (POAG) patients treated with 0.005 ...
Simin Zhu, Dabo Wang, Jing Han
doaj +1 more source
Ocular manifestations of Sturge–Weber syndrome: pathogenesis, diagnosis, and management [PDF]
, 2016 Sturge-Weber syndrome has been included in the group of phakomatoses that is characterized by hamartomas involving the brain, skin, and eyes. The characteristic facial port-wine stain, involving the first branch of the trigeminal nerve and the embryonic ...
Abdolrahimzadeh, Solmaz +4 more
core +1 more source